U.S. Markets close in 54 mins

Alnylam Pharmaceuticals Inc (ALNY) Files 10-K for the Fiscal Year Ended on December 31, 2018

- By insider

Alnylam Pharmaceuticals Inc (ALNY) files its latest 10-K with SEC for the fiscal year ended on December 31, 2018. Alnylam Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in developing novel therapeutics based on RNA interference, or RNAi. RNAi is a naturally occurring biological pathway within cells for regulating the expression of specific genes. Alnylam Pharmaceuticals Inc has a market cap of $8.82 billion; its shares were traded at around $83.03 with and P/S ratio of 89.05.


For the last quarter Alnylam Pharmaceuticals Inc reported a revenue of $21.0 million, compared with the revenue of $37.92 million during the same period a year ago. For the latest fiscal year the company reported a revenue of $74.9 million, a decrease of 16.7% from the previous year. For the last five years Alnylam Pharmaceuticals Inc had an average revenue growth rate of 12.7% a year.

The reported loss per diluted share was $7.57 for the year, compared with the loss per share of $3.45 in the previous year. The Alnylam Pharmaceuticals Inc had an operating margin of -1087.56%, compared with the operating margin of -556.2% a year before. The 10-year historical median operating margin of Alnylam Pharmaceuticals Inc is -146.16%. The profitability rank of the company is 2 (out of 10).

At the current stock price of $83.03, Alnylam Pharmaceuticals Inc is traded at 62.3% premium to its historical median P/S valuation band of $51.15. The P/S ratio of the stock is 89.05, while the historical median P/S ratio is 54.88. The stock lost 29.24% during the past 12 months.

For the complete 20-year historical financial data of ALNY, click here.

This article first appeared on GuruFocus.